Friday - February 27, 2026
Bayer's Xofigo Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases
February 27, 2026
WHIPPANY, New Jersey, Feb. 27 -- Bayer USA, an enterprise with core competencies in the life science fields of health care and nutrition, issued the following news:

* * *

Bayer's XOFIGO(R) (radium-223 dichloride) plus enzalutamide demonstrates significant overall survival benefit in PEACE-3 trial in patients with metastatic castration-resistant prostate cancer with bone metastases

* Final results for the key secondary endpoint of overall survival (OS) . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products